Lessons learnt to transition from Horizon 2020 to the new FP10 by Giuliana Miglierini The European Commission published the ex post evaluation of Horizon 2020 (H2020), the FP8 framework…
The risk of a biosimilar void in Europe by Giuliana Miglierini The undergoing revision of the pharmaceutical legislation aims, among others, to redefine data protection to…
Steps towards the final approval of the IP action plan By Giuliana Miglierini The end of 2021 may see the final approval of many pieces of the new…